We surveyed the following databases PubMed and Cochrane database using search terms NMO or Devic's disease AND pregnancy from January 2000 to June 2017 and reviewed each article for relevance. We searched PubMed also for each relevant immunosuppressive (IS) therapy used for NMO for pregnancy and breastfeeding-related issues. Additional searches were performed for issues relevant to infertility in NMO. We first describe established and theoretical biologic interactions between NMOSD and pregnancy based on current studies of AQP4 expression and immunologic changes in pregnancy in the opinions of the authors. We considered data relevant to management of other Abstract: Neuromyelitis optica spectrum disorders (NMOSD) predominantly affect women who are of childbearing age. Understanding the interactions between pregnancy and NMOSD is important for clinical management. Aquaporin-4 (AQP4), the most common target antigen in NMOSD, is expressed on placenta in early pregnancy. A variety of immune and cytokine changes in pregnancy may impact pregnancy outcomes in NMOSD patients. Relapses continue during pregnancy and increase in frequency postpartum. Preeclampsia and fetal loss are more frequent in NMOSD than in controls. Transfer of AQP4immunoglobulin G (IgG) from mother to baby occurs but appears not to cause disease. Several treatment options are relatively safe and mitigate the risk of relapse during pregnancy and postpartum. For patients with active NMOSD, it may be advisable to continue immunotherapy during pregnancy.
Introduction
Neuromyelitis optica spectrum disorders (NMOSD) are usually recurrent antibody-mediated inflammatory disorders with a predilection for optic nerve, spinal cord, area postrema of the medulla, and hypothalamus; they often have severe manifestations and sequelae. 1 Aquaporin4-immunoglobulin IgG (AQP4-IgG) is a specific diagnostic and pathogenic biomarker. 2 It binds to water channels on astrocyte foot processes, activating complement, thereby recruiting eosinophils and neutrophils resulting in astrocyte death and secondarily oligodendrocyte injury and axonal degeneration. 3 T-cell responses are polarized to proinflammatory T-helper (Th) 17 cells in NMOSD; 4 Th17 cytokines, interleukin-6 (IL-6), IL-17, and IL-23, are elevated in the blood of patients with neuromyelitis optica (NMO). 5, 6 NMOSD is two to nine times more common in women as in men. The mean age of onset is 30-40 years; consequently, many women with NMOSD experience onset of NMOSD during active childbearing years. 7 Genetic, epigenetic, or hormonal factors specific to women may influence NMOSD pathogenesis. 8 Relapses of multiple sclerosis (MS), the manifestations of which overlap with NMOSD, decrease in frequency during the third trimester of pregnancy; neither breast feeding nor epidural analgesia influence MS activity. 9 However, the pathophysiology of NMOSD and its response to immunotherapy differ from those of MS. We summarize the issues and data pertinent to interactions between NMOSD and pregnancy and propose reproductive management strategies for patients with NMOSD from preconception counseling to postpartum management. autoimmune diseases, especially safety data, in making recommendations. Our recommendations are based upon and reflect current recommendations regarding safety of immunosuppressant medication in pregnancy for a variety of autoimmune indications, and the current practice of the authors. Medication classification is based on US Food and Drug Administration (FDA) classifications as of 29 August 2017. e49 Class D medications are known to be embryo-and fetotoxic; however, normal newborns have been delivered in exposed women. Therefore, in rare instances, the potential benefits may warrant use of this drug despite potential risks. Class X medications are embryo-and fetotoxic and the risks involved in its use in pregnant women clearly outweigh potential benefits.
Pathogenesis of NMO during pregnancy
The reader is referred to a review by Davoudi et al., 10 regarding immunologic derangements in NMOSD and their impact on pregnancy, which are incompletely understood. Derangements in immunologic function in pregnancy and NMO are summarized in Table 1 based on established changes in immune function and changes in AQP4 in pregnancy that might be relevant to NMOSD disease activity.
AQP4 expression and AQP4 antibodies
AQP4 is expressed on placental syncytiotrophoblasts. Expression is highest during mid-gestation and decreases subsequently. 26 Saadoun et al. 27 induced placental necrosis in rodents by intraperitoneal administration of AQP4-IgG with co-injected human complement. Placental dysfunction is associated with preeclampsia, intrauterine growth restriction, and stillbirth, providing a potential mechanism for an increased frequency of these complications in NMOSD. Estrogen enhances AQP4 IgM subtypes switching to IgG through activation-induced cytidine deaminase expression 25 and additionally promotes leukocyte migration into central nervous system (CNS). 28 Sex hormones influence glycosylation of IgG glycoproteins during pregnancy which potentially might exacerbate NMOSD, considering that pathogenicity of AQP4-IgG is reduced by enzymatic de-glycosylation. 29 Quick and Cipolla 30 reported 10-fold upregulation of AQP4 in rodent brain during and after pregnancy; upregulation of AQP4 is associated with susceptibility of tissues to NMOSD attack, 31 which may increase the risk of NMOSD attacks or NMOSD-associated posterior reversible encephalopathy syndrome (PRES).
Immune subsets/cytokines T-cell subsets. NMOSD, like systemic lupus erythematosus (SLE) and myasthenia gravis (MG), has an important humoral component and is considered Th2 polarized relative to MS, which is Th1 polarized. e45-e47 NMOSD patients have higher numbers and proportions of Th17 cells compared to both MS and healthy controls 6 and IL-17 is elevated in peripheral blood. T cells exposed to AQP4 antigens in NMO have Th17 responses. 4 Th17 polarization stimulates production of chemokines including IL-8 and granulocyte-colony stimulating factor (G-CSF), recruiting granulocytes into brain lesions. In addition, IL17 can disrupt the blood brain barrier (BBB), allowing AQP4-IgG to reach the CNS. 32, 33 IL-6 is elevated in NMOSD; it is a key regulator of Th17/T-regulatory (T-reg) balance. 12 Unexplained recurrent spontaneous abortion (URSA), the frequency of which is increased in NMOSD, has been associated with excess Th17 cells in peripheral blood and decidua and deficient (T-reg) cells. 11, 12 Natural killer cells. Cytotoxic (CD16 + CD56 − ) natural killer cells (NKCs) are supplanted by anti-inflammatory (CD16 − CD56 + ) NKCs in healthy pregnancy. Reduced activity of MS disease during pregnancy is associated with increased blood (CD16 − CD56 + ) NKCs and shift to Th2 cytokines. [16] [17] [18] An increase in cytotoxic NKCs in peripheral blood and decidua has been reported in URSA. 19 Data are lacking about NKC subsets in NMOSD and specifically during pregnancy.
B cells and B-cell activating factor. Cells of B-cell lineage, specifically plasmablasts, are the source of AQP4-IgG; B-cell depletion is the mainstay of therapy for NMOSD. IL-6, which promotes plasmablast survival in addition to its aforementioned actions on promoting Th17 polarization of T cells, is elevated in serum and CSF of patients with NMOSD. 15 IL-6 is increased in normal pregnancy and pregnancy complications are accompanied by further increases in IL-6. 13, 14 Estrogens, which are elevated in pregnancy, increase synthesis of B-cell activating factor (BAFF) 21 and, in turn, enhance plasmablast survival; plasmablasts are the most important source of AQP4-IgG. 20 BAFF levels are elevated in CSF of patients with NMOSD and reduced with rituximab treatment. 22 Interferons. Treatment with interferon (IFN)-β exacerbates NMOSD. 34 Estrogen enhances type 1 IFN responses in plasmacytoid dendritic cells. e50 The downstream profile of protein expression induced by interferon-beta, specifically increased expression of phosphoserine signal transducer and activator of transcription (P-SSTAT1) and myxovirus resistance protein A (MxA) has been demonstrated in SLE and NMOSD but not MS. 24 Estrogen reduces murine IFN-γ production, shifting Th cell bias toward Th2. 23
NMOSD outcomes during pregnancy
Relapse rate, disability scale, and cofactors Retrospective studies have been conducted in seven populations ( Table 2) . [35] [36] [37] [38] [39] [40] Additional case reports describe pregnancy-related NMOSD experiences of interest. 41, 42 A synthesis of the data suggests that relapses occur at the same rate during pregnancy but an increased rate during the first 3 months postpartum compared to pre-pregnancy. [35] [36] [37] The mean disability increase ranges from 0.5 to 2 Expanded Disability Scale Score (EDSS) points at 1 year postpartum in different studies. Bourre et al. 39 reported EDSS increase of 2.1 points in 20 women after 1 year. Huang et al. 38 reported mean EDSS increase of 1.3 point in 18 of 62 women (29%) after 1 year. Fragoso et al. 37 reported mean EDSS increase of 1.7 in 17 women after 1 year. Shi et al. 40 report the nonsignificant mean EDSS increase of 0.5 points at 6 months in 16 women The first symptoms of NMOSD developed in 20%-47% of women during pregnancy or within 12 months of childbirth or miscarriage, 35, 38, 39, 43 a rate far higher than expected had pregnancy not been a contributing factor.
IS treatment was associated with reduced relapse rate (RR) during pregnancy. 35, 43 Shi et al. 40 found no reduction in RR during pregnancy when prednisone 10 mg per day was used as sole IS therapy in 5 of 8 (62.5%) patients although incremental pregnancy-associated disability was reduced (mean 0.25 EDSS points increase on IS therapy vs 0.75 points without (p = 0.038)). Huang et al. 38 reported that lack of preventative treatment (p = 0.012) and concomitant autoimmune diseases/autoantibodies (p = 0.025) were associated with increased RR during pregnancy. Maintenance immunotherapy treatment during pregnancy may reduce RR and prevent accumulating disabilities although formal evidence is lacking. Area postrema syndrome Intractable nausea and vomiting or hiccups reflecting inflammation of the area postrema are core clinical features of NMOSD and their recognition as an NMOSD syndrome may facilitate diagnosis and treatment. 44,e43 Hyperemesis gravidarum may be confused with the NMOSD-associated area postrema syndrome. 41, 45 Pregnancy outcomes in NMOSD
Infertility
Effects of NMOSD on fertility are unclear. Pregnancy rates are low, but this may reflect the relatively late age of onset of NMOSD (30-40 years) and conscious choice of NMOSD patients to avoid pregnancy, potentially due to existing or feared disability. Bove et al. 46 reported that 15 of 193 (8%) NMOSD respondents reported infertility of unidentified cause compared to 11 (6%) who had identified causes including ovarian cysts (n = 3), structural problems (n = 3, including 1 endometriosis), hormonal dysregulation (n = 3), and male factors (n = 2). An estimated 2% of women have primary infertility. e51
Miscarriages and fetal death NMOSD increased the risk of miscarriage 35, 38, 39 independent of risk of concomitant autoimmunity such as antiphospholipid syndrome. 43 43% of pregnancies ended in miscarriages after NMOSD onset compared to 7% before, usually in the first trimester; the association persisted after correction for differences in maternal age and prior miscarriage. 36 AQP4-IgG titers are not associated with the risk of miscarriage ( Table 2) .
Pre/eclampsia
Nour et al. 36 reported that eclampsia occurred at a rate much higher than in obstetric controls in pregnancies after NMOSD onset (11.5% vs 3.1%; p = 0.0001). 40 Concurrent autoimmune diseases but neither maternal age nor age at onset were risk factors. HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, which is linked to preeclampsia, was reported in one patient at 31 weeks of gestational along with PRES. 47 PRES has been reported in NMOSD case series 48 and loss of AQP4 expression and function leading to cellular swelling has been implicated in mice models. e48
Passive disease transfer AQP4-IgG is elevated for 1-3 months in serum of neonates born to women with NMOSD. 38,41,43,49,e44 There have been no clinical manifestations of NMOSD although AQP4 is expressed by 14 weeks in fetal CNS; 50 lack of passive transfer to neonates is compatible with failure to experimentally induce NMOSD with passive antibody transfer in rodents. e1 However, autoantibodies that are often coexistent with AQP4-IgG are potentially transferable, including anti-Ro antibodies in patients with Sjogren's syndrome which may lead to congenital heart block or acetylcholine receptor autoantibodies which may lead to transient neonatal MG. e2,e3 It is reasonable to screen for such antibodies, especially anti-Ro, which are present in more than 10% of NMOSD patients.
Spinal anesthesia and NMOSD
Spinal anesthesia has generally been found safe in NMOSD. [35] [36] [37] [38] [39] However, NMOSD began in five patients within 6 months of epidural or spinal anesthesia (n = 3) e4,e5 or relapsed postpartum (n = 2); e6-e8 three of the five patients received bupivacaine. Recommendations are difficult based on limited case reports, but one might consider avoiding bupivacaine for spinal anesthesia.
IS treatment considerations in pregnancy in NMO patients
Acute relapse treatments Intravenous corticosteroids (Class C). Antenatal highdose corticosteroids were used during pregnancy at different gestation stages in NMO patients 38,43,42,e8,e10,e11 with no apparent fetal complications, except for low birthweight compared to those did not receive (2444 ± 440 vs 3060 ± 466 g, p = 0.002). 38 Repeated steroid during pregnancy, specifically four doses of dexamethasone 6 mg every 12 hours weekly for 2-3 weeks, is associated with low head circumference compared to controls who did not receive corticosteroids (30.7 ± 0.1.0 cm vs 31.6 ± 1.1 cm, p = 0.004) and in those who received a single course (31.1 ± 1.3, p = 0.049). The regimen was also associated with low birthweight (2133 ± 298 g vs 2352 ± 390 g, p = 0.011 in untreated controls and 2319 ± 312 g, p = 0.021 in those who received a single course). e12,e13
Plasmapheresis. Plasmapheresis (PLEX) has been safely administered at various gestational stages in NMOSD patients, 36,41,43,e8,e9,e14 and in other autoimmune diseases including SLE. e15
Intravenous immunoglobulin (Class C). Intravenous immunoglobulin (IVIG) has been used in pregnancy to treat immune thrombocytopenic purpura, immunodeficiency syndromes, MG, and other autoimmune diseases. IVIG has been used for acute attacks of NMOSD outside of pregnancy with apparent benefit. e16 IVIG toxicity in pregnancy is inadequately studied, but considered generally safe. e17-e19 However, it was associated with low birthweight compared to those did not receive (2444 ± 440 g vs 3060 ± 466 g, p = 0.002) 38,e6 and can cross the placenta after 32 weeks gestation.
Maintenance of IS therapies
Azathioprine (FDA Class D). Azathioprine has been administered without apparent complication throughout pregnancy and breast feeding in a variety of autoimmune conditions. e20-e22 In 3124 women, there was no excess of low birthweight, preterm birth, conception failures, miscarriage, birth defect, major congenital malformations, or neoplasia compared to those not receiving azathioprine. e20,18 Azathioprine metabolites were very low or undetectable in milk samples of 10 breastfeeding women who took azathioprine. Deficient fetal inosinate pyrophosphorylase enzyme that converts azathioprine to its active metabolite, 6-thioguanine nucleotides, may protect the infant. e22 Azathioprine (50-250 mg/day) was administered to nine NMOSD pregnant patients, alone or combined with corticosteroids; there was one miscarriage and one premature birth. 36, 37, 40, 43 Rituximab (FDA Class C). Rituximab crosses the placenta from week 16 onwards and depletes maternal and fetal B cells. Among 153 patients with a variety of conditions treated with rituximab during the first trimester for a variety of indications, 33 (21%) had miscarriages and 2% had congenital malformation, e24 similar to expected rates in the general obstetric population. e52 Hematologic abnormalities occurred in 11 (12%) neonates, the commonest being B-cell depletion (n = 4). No serious infections were reported aside from a single report of cytomegalovirus infection in mother complicated by cytomegalovirus hepatitis in the infant. e24 Two NMOSD patients received rituximab prior to pregnancy, 49,e25 one of whom received 1000 mg a week prior to conception and the second 100 mg,7 months before pregnancy; neither relapsed during pregnancy and their children were healthy aside from transient B-cell lymphopenia. The first patient developed a relapse 10 days postpartum, despite undetectable B cells.
Mycophenolate mofetil (FDA Class D). Mycophenolate mofetil (MMF) is relatively contraindicated in breast feeding and pregnancy because of a high rate of fetal anomalies associated with MMF, especially cleft lip and palate and ear malformations. Major congenital malformations occurred in 4 of 15 (27%) children born to transplant patients who received MMF e26 and 6/29 (21%) infants of prospectively followed patients who received mycophenolate during pregnancy. e27 The expected rate of major congenital malformation is 3%. e52
Methotrexate (FDA Class X). Methotrexate (MTX) is contraindicated in pregnancy and while breast feeding. e28 MTX can cause immune suppression, neutropenia, carcinogenesis, and adverse effects on development. e29 However, two Brazilian NMOSD patients were treated during pregnancy with MTX for unknown duration and uncertain dose with no apparent fetal injury or NMOSD relapse. 37 Cyclophosphamide (FDA Class D). Cyclophosphamide is contraindicated during pregnancy and breastfeeding, but one reported use has been reported in a patient with NMOSD whose pregnancy was uneventful. 37 However, four of four pregnant SLE patients exposed to cyclophosphamide in early or mid-pregnancy experienced fetal loss after administration (100% vs 31.25% individuals of comparable disease severity not treated with cyclophosphamide). e30
Oral corticosteroids (FDA Class C; FDA Class D in first trimester). Oral corticosteroids have been continued during pregnancy in NMOSD 29, 38, 40 and other conditions, e31 at the lowest possible dose, typically less than 20 mg per day. Prednisone is metabolized by the placenta; only 10% crosses into the fetal circulation. In a case control study of approximately 1800 individuals with cleft lip with or without cleft palate, corticosteroids were associated with cleft lip and palate that occurred in 33 infants (odds ratio: 1.7; 95% confidence interval (CI): 1.1-2.6), but not with cleft lip. e32 However, in a meta-analysis of retrospective and prospective studies including 84,184 instances in which the infant had been exposed to corticosteroids during pregnancy, no risk of orofacial clefts was associated with the use of corticosteroids. e33,e34 The absolute risk of facial cleft after prenatal exposure to corticosteroids is small; therefore, corticosteroids may be judiciously continued, if necessary, preferably at doses of 10 mg/day or less, especially during the first trimester.
Management recommendations

Preconception counseling
Fertility is not known to be affected by NMOSD. Hormonal contraception does not reduce the efficacy of attack prevention medications except for MMF, which is teratogenic, and contraindicated in women planning to conceive. Azathioprine e20-e22, 36, 37, 40, 43 and rituximab 49,e24,e25 are considered relatively safe and the preferred immunosuppressants for administration in pregnancy. However, the decision to continue these medications during pregnancy must balance risks of NMOSD attack versus uncertain risks of therapy. When NMOSD has been active, maintenance immunosuppression during pregnancy should be continued during pregnancy and especially postpartum.
Transient passive transfer of AQP4-IgG occurs but appears not to cause disease. Risk of genetic transmission is low and compatible with risks of other complex multifactorial diseases; NMOSD is familial in 3% of affected individuals; multiple affected relatives have rarely been reported in a single pedigree. e35
Management of acute relapse during pregnancy IVIG and PLEX may be used for corticosteroidrefractory attacks. For patients who have intractable nausea vomiting or hiccup who have established NMOSD, one should obtain a magnetic resonance imaging (MRI) brain and cervical spine to rule out area postrema syndrome. One should consider testing for AQP4-IgG in patients with intractable nausea, vomiting, or hiccup, particularly if there is a history of other indicators of NMOSD, such as symptoms compatible with optic neuritis or myelitis.
IS therapies
In keeping with contemporary expert practice, the authors recommend that MMF should be discontinued 6 weeks and MTX and cyclophosphamide 3 months prior to planned conception e36,e37 and alternative immunosuppression should be administered to reduce RR during pregnancy and then EDSS. 35, 40, 43 Azathioprine Azathioprine may be continued with reasonable safety alone at the recommended dose of 2 Neonates should be evaluated for medication side effects, especially hematologic, or for symptoms that might be related to passively transferred antibodies depending on the serostatus of the mother (e.g. seropositive for acetylcholine receptor antibodies or anti-Ro antibodies).
Postpartum follow-up
IS treatment should be resumed as soon as possible, but MTX, cyclophosphamide, and MMF should be avoided during lactation. It is advisable to postpone lactating 4 hours after azathioprine and corticosteroid treatment. e28 For patients with recently active NMOSD, early weaning within several weeks and reinitiation of IS disease should be considered. For patients on medications that do not impact breastfeeding, breastfeeding need not be otherwise restricted for NMOSD-related reasons.
Conclusion
NMOSD remains active during pregnancy and the RR increases postpartum. The rate of fetal loss and preeclampsia are increased. Rituximab and azathioprine therapy are likely safe and in patients with active disease should be considered as maintenance treatment throughout pregnancy and the postpartum period. Registries of pregnant NMOSD patients will assist with refinement of management recommendations.
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